Verrica Pharmaceuticals (NASDAQ:VRCA), a dermatology-focused therapeutics company, reported financial results for the fourth quarter and full year ended December 31, 2025, on Wednesday.
The results highlight a sharp acceleration in the commercial adoption of YCANTH, the first FDA-approved treatment for molluscum contagiosum, alongside a significant narrowing of the company’s net loss.
Net product revenue for the fourth quarter jumped to $3.7 million, a substantial increase from the $0.3 million reported in the same period of 2024.
Management attributed the growth to heightened demand from distribution partners for YCANTH.
Additionally, the company recognized $1.4 million in license and collaboration revenue, primarily tied to the commercial supply for the product's launch in Japan via its partner, Torii Pharmaceutical.
The company’s fiscal health showed marked improvement through disciplined cost management and debt reduction.
Selling, general, and administrative (SG&A) expenses fell to $8.1 million, down from $9.9 million a year prior, as the company optimized its commercial activities.
Furthermore, interest expense decreased by $1 million following the total repayment and termination of Verrica’s credit agreement in November 2025.
For the quarter ended December 31, 2025, Verrica reported a net loss of $8.1 million, or $0.57 per share, compared to a net loss of $16.2 million, or $2.41 per share, in the prior-year period.
On a non-GAAP basis, the net loss was $7.2 million, or $0.51 per share.